drugset
drugset / Trial / NCT00077467

Bortezomib in Treating Young Patients With Refractory or Recurrent Leukemia

NCT00077467 ↗

Phase 1 Completed 36 enrolled National Cancer Institute (NCI)
NaSingle-groupOpen-labelTreatment

Summary

This phase I trial is studying the side effects and best dose of bortezomib in treating young patients with refractory or recurrent leukemia. Bortezomib may stop the growth of cancer cells by blocking the enzymes necessary for their growth.

Timeline

Start
2004-01
Primary completion
2006-03
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject Bortezomib Small molecule — Intravenous

Indications

acute promyelocytic leukemia blast phase chronic myelogenous leukemia, BCR-ABL1 positive childhood acute lymphoblastic leukemia childhood acute myeloid leukemia